To compete with Airbnb along with other homesharing companies, Marriott International is reportedly starting a business for home shares. Unnamed sources claim the firm could soon debut details for the first phase of the plan, The Wall Street Journal reported. It was also reported that Marriott would enable guests of home shares to earn and redeem loyalty points.
Ryan Meliker, who has served as a lodging analyst and hotel investor, told the outlet, “It’s clear that the homesharing phenomenon is here to stay, and hotel companies want to make sure they get their piece of this pie.”
Beyond Marriott, hotel operators such as Hyatt Hotels and Hilton Worldwide Holdings are also said to be looking into the home rentals business. The report noted that some executives who initially dismissed HomeAway and Airbnb as rivals have now come to think they are expanding partially at the expense of hotel companies, particularly when it comes to large families and leisure travelers.
The news comes as some homesharing marketplaces are getting into the hotel business: News surfaced that Airbnb had acquired HotelTonight, which is a firm that helps consumers locate discounted hotel rooms. The move was said to be a step toward expanding Airbnb’s business and bringing in a broader base of customers, such as those who enjoy exploring but don’t want to stay in a person’s home.
With the move, Airbnb was reportedly in competition with more traditional travel sites such as Travelocity, Priceline and Expedia. It was also said that the company’s inventory would grow to encompass hotel listings separate from the site’s home listings. While the deal’s terms were not disclosed, HotelTonight’s last valuation was US$463 million in 2017. Airbnb Chief Executive Officer Brian Chesky said, per reports at the time, that buying the hotel site was “a big part of building an end-to-end travel platform.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas